HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Frank S Czerwiec Selected Research

Creatinine

11/2017Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.
11/2016Prognostic Enrichment Design in Clinical Trials for Autosomal Dominant Polycystic Kidney Disease: The TEMPO 3:4 Clinical Trial.
11/2016Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial.
1/2016Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.
6/2015Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
12/2012Tolvaptan in patients with autosomal dominant polycystic kidney disease.
5/2011Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Frank S Czerwiec Research Topics

Disease

29Autosomal Dominant Polycystic Kidney (ADPKD)
06/2020 - 05/2011
6Disease Progression
01/2019 - 08/2011
6Hyponatremia
04/2017 - 11/2006
4Cysts
12/2012 - 05/2011
3Chronic Renal Insufficiency
10/2021 - 12/2013
3Polycystic Kidney Diseases (Polycystic Kidney Disease)
01/2018 - 05/2011
2Nocturia
06/2020 - 01/2017
2Chronic Kidney Failure (Chronic Renal Failure)
05/2017 - 05/2017
2Inappropriate ADH Syndrome (SIADH)
04/2017 - 05/2011
2Pain (Aches)
02/2017 - 12/2012
2Polyuria
01/2017 - 04/2010
2Heart Failure
11/2015 - 11/2006
2Fibrosis (Cirrhosis)
11/2015 - 11/2006
1Rare Diseases (Rare Disease)
08/2017
1Neoplasms (Cancer)
04/2017
1Kidney Diseases (Kidney Disease)
02/2017
1Urinary Tract Infections (Urinary Tract Infection)
02/2017
1Kidney Calculi (Kidney Stone)
02/2017
1Hematuria
02/2017
1Albuminuria
11/2016
1Hypernatremia
01/2016
1Chemical and Drug Induced Liver Injury
11/2015
1Hypertension (High Blood Pressure)
10/2011
1Fatigue
04/2010
1Polydipsia
04/2010
1Intermittent Claudication
08/2004

Drug/Important Bio-Agent (IBA)

32TolvaptanFDA Link
06/2020 - 11/2006
15TEMPOIBA
02/2019 - 05/2011
10Vasopressins (Vasopressin)IBA
01/2019 - 11/2006
7Vasopressin Receptors (Arginine Vasopressin Receptor)IBA
06/2020 - 05/2011
7CreatinineIBA
11/2017 - 05/2011
4SodiumIBA
04/2017 - 11/2006
3Biomarkers (Surrogate Marker)IBA
01/2019 - 05/2017
3Transaminases (Aminotransferases)IBA
11/2017 - 11/2015
3ElectrolytesIBA
04/2017 - 11/2006
3Antidiuretic Hormone Receptor AntagonistsIBA
10/2011 - 04/2010
2Pharmaceutical PreparationsIBA
05/2017 - 08/2004
2SaltsIBA
04/2017 - 05/2011
1TabletsIBA
06/2020
1BilirubinIBA
11/2017
1Edetic Acid (EDTA)FDA Link
08/2017
1Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA
06/2017
1Arginine Vasopressin (Argipressin)IBA
01/2017
1AlbuminsIBA
11/2016
1Cyclic AMP (AMP, Cyclic)IBA
08/2011
1Cilostazol (Pletal)FDA LinkGeneric
08/2004
1Phosphoric Diester Hydrolases (Phosphodiesterases)IBA
08/2004
1Adenosine (Adenocard)FDA LinkGeneric
08/2004
1Cyclic NucleotidesIBA
08/2004

Therapy/Procedure

4Therapeutics
10/2021 - 11/2006
2Treatment Delay
01/2018 - 01/2017
1Aftercare (After-Treatment)
06/2016